WASHINGTON _ President Donald Trump is promising emergency approval of a drug produced by Regeneron, which he credits with his own swift recovery from COVID-19, as a way to appeal to senior citizens who are breaking sharply away from his campaign over his response to the pandemic.
The last-ditch effort to shore up a voting demographic that was key to his victory in 2016 has raised new concerns among clinicians and infectious disease experts that the antibody cocktail, which is in early clinical trials, will receive fast-tracked approval well before sufficient data is collected on its safety and effectiveness.
